TG Therapeutics, Inc. (TGTX): Total Liabilities
$415.23M
As of 2025-12-31
$1.04B
As of 2026-06-30
+45.4%
3-year compound annual growth
+31.3%
5-year compound annual growth
+42.7%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $415.23M | +16.9% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $355.33M | +110.1% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $169.09M | +25.3% | 2025-03-03, Balance as of period end |
| 2022-12-31 | $134.99M | -5.3% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $142.48M | +34.0% | 2023-03-01, Balance as of period end |
| 2020-12-31 | $106.29M | -14.6% | 2022-03-01, Balance as of period end |
| 2019-12-31 | $124.40M | +108.8% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $59.58M | +96.1% | 2020-03-02, Balance as of period end |
| 2017-12-31 | $30.39M | +60.7% | 2019-03-01, Balance as of period end |
| 2016-12-31 | $18.91M | +58.9% | 2018-03-15, Balance as of period end |
| 2015-12-31 | $11.90M | +79.1% | 2017-03-16, Balance as of period end |
| 2014-12-31 | $6.65M | -17.5% | 2016-03-15, Balance as of period end |
| 2013-12-31 | $8.06M | +23.5% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $6.52M | +33.1% | 2014-03-07, Balance as of period end |
| 2011-12-31 | $4.90M | n/a | 2013-03-21, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $415.23M | +16.9% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $663.99M | -20.5% |
| Insmed Inc (INSM) | 2025-12-31 | $1.53B | -12.3% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $601.51M | +17.6% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.60B | +29.3% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $501.83M | -0.1% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $390.93M | +17.6% |
Compare TGTX, OPK, INSM, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗